Investor Presentaiton
Novo Nordisk Annual Report 2023
Statement of ESG performance
for the year ended 31 December
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information.
Note
2023
2022
2021
Note
2023
2022
2021
Environmental performance
Social performance (continued)
Energy consumption for operations (1,000 GJ)
7.1
3,784
3,677
Share of renewable power for production sites
7.1
100%
100%
3,387
100%
Societies
Scope 1 emissions (1,000 tonnes CO₂e)¹
7.2
78
76
77
Change in average net price across US product portfolio (% change to previous year)
Change in average net price across US insulin portfolio (% change to previous year)
8.6
(8.2%)
(10.5%) (12.3%)
8.6
(24.4%)
(19.5%)
(10.9%)
Scope 2 emissions (1,000 tonnes CO₂e)¹
Scope 3 emissions (1,000 tonnes CO₂e)1.2
Waste from production sites (tonnes)
7.2
15
16
16
Total tax contribution (DKK million)
8.7
51,247
36,003
32,593
7.2
3,738
2,418
N/A
Donations and other contributions (DKK million)
8.8
138
126
92
Water consumption for production sites (1,000 m³)
7.3
4,150
7.4
189,091
3,918
213,505
3,488
180,806
Governance performance
Business ethics reviews
9.1
40
35
37
Breaches of environmental regulatory limit values³
7.5
12
8
8
Employees trained in business ethics
9.1
99%
99%
98%
Social performance
Patients
Number of substantiated cases reported via the Compliance Hotline
Convictions for violation of anti-corruption and anti-bribery laws
9.2
314
288
236
9.2
-
Patients reached with Novo Nordisk's Diabetes and Obesity care products (in millions)4
• Hereof reached via the Novo Nordisk Access to Insulin Commitment (in millions)
888
8.1
41.6
36.9
34.9
Supplier audits
9.3
382
294
253
8.1
2.4
1.8
1.7
Product recalls
9.4
2
3
1
Children reached through the Changing Diabetes® in Children programme
(cumulative)
Failed inspections
9.5
8.1
52,249
41,033
31,846
Facilitations of the Novo Nordisk Way
9.6
People and employees
Year-end employees (total)
Employee turnover
Company reputation (scale 0-100)
9.7
82.1
|ཝ༴
42
36
34
82.3
82.6
8.2
64,319
8.2
5.5%
55,185
8.2%
48,478
11.0%
Animals purchased for research
9.8
56,508
79,750
47,879
Gender in leadership positions (ratio men:women)
8.3
54:46
56:44
Gender in senior leadership positions (ratio men:women)
Gender in the Board of Directors (ratio men:women)
Sustainable employer score
8.3
59:41
61:39
57:43
64:36
1.2023 is the first year of reporting all emission categories in CO₂e. Comparative figures for scope 1, 2 and part of scope 3 emissions are measured in CO2. Refer to section
7.2 for further details. 2. 2022 was the first year of full scope 3 emissions' disclosure, which in 2021 and previously was limited to business flights and product distribution.
3. The methodology for counting number of breaches has changed in 2023. Comparative figures are adjusted accordingly. 4. 2023 is the first year of reporting Obesity as
part of number of patients reached. Comparative figures are adjusted accordingly.
8.3
50:50
54:46
67:33
8.4
86%
85%
84%
Frequency of occupational accidents (number per million working hours)
8.5
1.5
1.5
1.3
98
86View entire presentation